Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Keros Therapeutics Inc is a biotechnology business based in the US. Keros Therapeutics shares (KROS) are listed on the NASDAQ and all prices are listed in US Dollars. Keros Therapeutics employs 44 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$38.14|
|52-week range||$28.50 - $86.80|
|50-day moving average||$35.19|
|200-day moving average||$44.44|
|Wall St. target price||$86.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.41|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-4.22%|
|1 month (2021-09-22)||23.83%|
|3 months (2021-07-22)||0.63%|
|6 months (2021-04-22)||-39.48%|
|1 year (2020-10-21)||-26.85%|
|2 years (2019-10-18)||N/A|
|3 years (2018-10-18)||N/A|
|5 years (2016-10-18)||N/A|
|Gross profit TTM||$-32,538,000|
|Return on assets TTM||-17.94%|
|Return on equity TTM||-28.76%|
|Market capitalisation||$909.9 million|
TTM: trailing 12 months
There are currently 1.0 million Keros Therapeutics shares held short by investors – that's known as Keros Therapeutics's "short interest". This figure is 20.8% up from 855,034 last month.
There are a few different ways that this level of interest in shorting Keros Therapeutics shares can be evaluated.
Keros Therapeutics's "short interest ratio" (SIR) is the quantity of Keros Therapeutics shares currently shorted divided by the average quantity of Keros Therapeutics shares traded daily (recently around 291021.12676056). Keros Therapeutics's SIR currently stands at 3.55. In other words for every 100,000 Keros Therapeutics shares traded daily on the market, roughly 3550 shares are currently held short.
However Keros Therapeutics's short interest can also be evaluated against the total number of Keros Therapeutics shares, or, against the total number of tradable Keros Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Keros Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Keros Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0715% of the tradable shares (for every 100,000 tradable Keros Therapeutics shares, roughly 72 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Keros Therapeutics.
Find out more about how you can short Keros Therapeutics stock.
We're not expecting Keros Therapeutics to pay a dividend over the next 12 months.
Keros Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.